Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: A case report

Annals of Clinical Microbiology and Antimicrobials

Volumn 1, Issue , 2002, Pages

  Gökengin, Deniz ^a   Yamazhan, Tansu ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; AZITHROMYCIN; DIAZEPAM; ELECTROLYTE; INDINAVIR; LAMIVUDINE; LITHIUM DERIVATIVE; LIVER ENZYME; NEVIRAPINE; PAROXETINE; SERTRALINE; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CRYPTOSPORIDIOSIS; DEPRESSION; DIARRHEA; DRUG WITHDRAWAL; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPEREMIA; LIVER FUNCTION TEST; LIVER TOXICITY; MALAISE; MEDICAL SCHOOL; NAUSEA; SEBORRHEIC DERMATITIS; TURKEY (REPUBLIC);

EID: 3042653079     PISSN: 14760711     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-0711-1-1     Document Type: Article

References (12)

1. Reisler R, Liou S, Servoss J, Robbins G, Theodore D, Murphy R, Chung R: Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials. Program and abstracts of The 1st IAS Conference on HIV Pathogenesis and Treatment; Buenos Aires, Argentina. Abstract 43July 8-11, 2001
2. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of Hepatitis C or B virus infection. JAMA 2000, 283:74-80
3. Johnson S, Baraboutis JG: Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA 2000, 284:2722-2723
4. Centers for Disease Control: Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-Worldwide, MMWR 2000, 49:1997-2001
5. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, et al: Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001, 15:1261-1268
6. Dieterich D, Stern J, Robinson P, Hall D, Carlier H: Analyses of four key clinical trials to assess the risk of hepatotoxicity with nevirapine: Correlation with CD4+ levels, hepatitis B and C seropositivity, and baseline liver function tests. Program and abstracts of The 1st IAS Conference on HIV Pathogenesis and Treatment; Buenos Aires, Argentina. Abstract 44July 8-11, 2001
7. Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ: Risk factors for hepatotoxicity in HIV-1 infected patients receiving ritonavir and saquinavir with or without stavudine, Prometheus Study Group. Clin Infect Dis 2000, 31:1234-1239
8. Prakash M, Vijayrama P, Tiyyagura L, Bonacini M: Jaundice and hepatocellular damage associated with nevirapine therapy. Am J Gastroenterol 2001, 96:1571-1574
9. Piliero PJ, Purdy B: Nevirapine-induced hepatitis: a case series and review of the literature. AIDS Read 2001, 11:379-382
10. Davis M: Hepatotoxicity of antidepressants. Int Clin Psychopharmacol 1991, 6:97-103
11. Dostert P, Benedetti MS: Biochemical mechanisms of the hepatotoxicity of psychotropic drugs. Encephale 1984, 10:199-209
12. Panel on Clinical Practices for the Treatment of HIV: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. [http://www.hivatis.org/trtgdlns.html#Adult]August 13,2001